FDA clears Celgene’s sNDA for mantle cell lymphoma drug candidate
The approval follows positive data from MCL-001 phase II, multi-center study of lenalidomide, which was conducted in 134 MCL patients previously treated with rituximab, cyclophosphamide, an anthracycline (or
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.